Trial Profile
A trial of X4P-001 in patients with solid tumours
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2018
Price :
$35
*
At a glance
- Drugs Mavorixafor (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors X4 Pharmaceuticals
- 17 Dec 2015 New trial record